Relugolix/enzalutamide trial to “bridge the gap” between STAMPEDE and PROTEUS trials

In this video, Kelly L. Stratton, MD, FACS, offers mre details on a phase 1B trial evaluating relugolix (Orgovyx) and enzalutamide (Xtandi) for high-risk prostate cancer. Stratton is an associate professor of urologic oncology at the University of Oklahoma, Oklahoma City.

Transcription:

Patients will receive 6 months of combined hormonal therapy; again, that's with relugolix and enzalutamide. And then depending upon whether they would prefer surgery or radiation to undergo local treatment, patients have the option of selecting either radiotherapy or surgery. And then for 18 months after that, they'll continue with combined hormonal therapy. The total duration of hormonal therapy will be 2 years. And that really is important because we see that there's a benefit to combined hormonal therapy. For instance, in the STAMPEDE trial, patients underwent 2 years of combined treatment, those that were not metastatic but high risk, and it appeared that in that study, androgen deprivation therapy with abiraterone was beneficial. We're also awaiting some additional studies to report, and so we feel like it's important to be prepared for those studies. For instance, the PROTEUS study looked at combined hormonal therapy and surgery. In that protocol, patients received 1 year of combined treatment with ADT plus an anti-androgen drug, and they underwent surgery at 6 months and then continued on for another 6 months. So this study really bridges the gap between STAMPEDE and PROTEUS and provides the opportunity for patients to get either surgery or radiation therapy.

This transcription was edited for clarity.